An Open-Label Study of Pegylated Liposomal Doxorubicin, Vincristine, and Reduced-Dose Dexamethasone Combination Therapy in Newly Diagnosed Multiple Myeloma Patients in the Chinese Population
OBJECTIVE Though doxorubicin is highly active in the treatment of multiple myeloma, its toxicity profile limits its therapeutic index. We performed this study to evaluate the effi cacy and safety of pegylated liposomal doxorubicin (PLD, Caelyx®), vincristine, and reduced-dose dexamethasone combi...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
China Anti-Cancer Association
2009-12-01
|
| Series: | Cancer Biology & Medicine |
| Subjects: | |
| Online Access: | http://www.cancerbiomed.org/index.php/cocr/article/view/244 |